Investment
Features
FeesSafety
Academy
More
Pluang+

Compare W W Grainger Inc (GWW) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

W W Grainger IncTrade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

W W Grainger Inc vs Vaxcyte Inc. Common Stock — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.41B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: W W Grainger Inc is far larger — about 5.9× Vaxcyte Inc. Common Stock's market cap, and W W Grainger Inc pays a 0.75% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

GWWPCVX
Market Cap
$62.41B$10.51B
Volume
284,7152,644,694
Sector
IndustrialsHealth
52-Week High
$1.40K$73.82
52-Week Low
$918.18$40.32
Typical Hold Time
26 Days0 Days
Enterprise Value
$64.62B$9.14B
Dividend Yield
0.75%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

W W Grainger Inc

GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.

Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GWW
100% Buy0% Sell
Avg holding period · 26 Days
PCVX
100% Buy0% Sell
Avg holding period · 0 Days

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →